A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00836082
First received: January 12, 2009
Last updated: August 5, 2009
Last verified: August 2009
  Purpose

To determine if PF-04457845 at doses of 0.5mg, 1mg, 4mg, and 8 mg given once daily for 14 days will be safe and well tolerated in healthy volunteers. To determine the effect on food on PF-04457845 pharmacokinetics and safety following administration of single doses of 4mg and 8mg.


Condition Intervention Phase
Acute Pain
Chronic Pain
Drug: PF-04457845, FAAH inhibitor
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Official Title: A Phase 1, Double-Blind (Sponsor Open), Randomised, Placebo-Controlled, Parallel Group, Oral Multiple-Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04457845 In Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • To characterize the multiple-dose pharmacokinetics of PF-04457845. [ Time Frame: 14 Days ] [ Designated as safety issue: No ]
  • To characterize the relationship between PF-04457845 and the level of anandamide and level of FAAH enzyme inhibition in healthy adult volunteers following multiple dosing. [ Time Frame: 14 Days ] [ Designated as safety issue: No ]
  • To evaluate the safety and tolerability of multiple oral doses of PF-04457845. [ Time Frame: 14 Days ] [ Designated as safety issue: Yes ]
  • To determine the effect on food on PF-04457845 pharmacokinetics following administration of single doses of 4mg and 8mg. [ Time Frame: 7-14 Days ] [ Designated as safety issue: No ]
  • To determine the effect on food on PF-04457845 safety following administration of single doses of 4mg and 8mg. [ Time Frame: 7-14 Days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • CogState/GMLT [ Time Frame: 14 Days ] [ Designated as safety issue: No ]
  • Telemetry [ Time Frame: 14 Days ] [ Designated as safety issue: No ]
  • Neurologic Exam [ Time Frame: 14 Days ] [ Designated as safety issue: No ]

Enrollment: 41
Study Start Date: February 2009
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1 (N=10)
Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days.
Drug: PF-04457845, FAAH inhibitor
Oral solution of 0.5mg given once daily for 14 days.
Experimental: Cohort 2 (N=10)
Placebo-controlled, escalating multiple doses of 1mg per day for 14 days.
Drug: PF-04457845, FAAH inhibitor
Oral solution of 1mg given once daily for 14 days.
Experimental: Cohort 3 (N=10)
Placebo-controlled, escalating multiple doses of 4mg per day for 14 days.
Drug: PF-04457845, FAAH inhibitor
Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
Drug: PF-04457845, FAAH inhibitor
A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
Experimental: Cohort 4 (N=10)
Placebo-controlled, escalating multiple doses of 8mg per day for 14 days.
Drug: PF-04457845, FAAH inhibitor
Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
Drug: PF-04457845, FAAH inhibitor
A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase

  Eligibility

Ages Eligible for Study:   21 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and/or female subjects (of non childbearing potential) between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
  • Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs).
  • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including hyperlipidemia), pancreatic, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • History of febrile illness within 5 days prior to the first dose.
  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • A positive urine drug screen.
  • History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
  • Treatment with an investigational drug within 30 days ( or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
  • 12-lead ECG demonstrating QTc >450 msec at screening. If QTc exceeds 450msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
  • Females of childbearing potential.
  • Use of prescription or nonprescription drugs, and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements and hormonal replacement therapy must be discontinued 28 days prior to the first dose of study medication. As an exception, ibuprofen may be used at doses of up to 1800 mg/day with food. Limited use of non-prescription medications that are not believed to affect subject safety or overall results of the study may be permitted on a case -by-case basis following approval by the sponsor.
  • Unwillingness to refrain from consumption of grapefruit or grapefruit/pomelo containing products within 7 days prior to the first dose of study medication until the completion of the follow-up visit.
  • Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.
  • Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
  • Subject is the Investigator or sub-Investigator. research assistant, pharmacist, study coordinator, other staff, or a relative of study personnel directly involved with the conduct of the study.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  • The use of marijuana (or other illicit drugs) within 30 days of randomization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00836082

Locations
Singapore
Pfizer Investigational Site
Singapore, Singapore, 188770
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00836082     History of Changes
Other Study ID Numbers: B0541002
Study First Received: January 12, 2009
Last Updated: August 5, 2009
Health Authority: Singapore: Health Sciences Authority

Keywords provided by Pfizer:
Healthy volunteers

Additional relevant MeSH terms:
Chronic Pain
Acute Pain
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on October 19, 2014